These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713 [TBL] [Abstract][Full Text] [Related]
6. HPW-RX40 restores anoikis sensitivity of human breast cancer cells by inhibiting integrin/FAK signaling. Chen IH; Shih HC; Hsieh PW; Chang FR; Wu YC; Wu CC Toxicol Appl Pharmacol; 2015 Dec; 289(2):330-40. PubMed ID: 26386190 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592 [TBL] [Abstract][Full Text] [Related]
8. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Carrasco-García E; Saceda M; Grasso S; Rocamora-Reverte L; Conde M; Gómez-Martínez A; García-Morales P; Ferragut JA; Martínez-Lacaci I Exp Cell Res; 2011 Jun; 317(10):1476-89. PubMed ID: 21439954 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors. Gagliano T; Gentilin E; Tagliati F; Benfini K; Di Pasquale C; Feo C; Falletta S; Riva E; degli Uberti E; Zatelli MC Biochem Pharmacol; 2015 Dec; 98(4):639-48. PubMed ID: 26484875 [TBL] [Abstract][Full Text] [Related]
11. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554 [TBL] [Abstract][Full Text] [Related]
12. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511 [TBL] [Abstract][Full Text] [Related]
13. The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway. Liu M; Yang Y; Wang C; Sun L; Mei C; Yao W; Liu Y; Shi Y; Qiu S; Fan J; Cai X; Zha X Arch Biochem Biophys; 2010 Oct; 502(2):89-95. PubMed ID: 20650261 [TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin. Orecchia A; Lacal PM; Schietroma C; Morea V; Zambruno G; Failla CM J Cell Sci; 2003 Sep; 116(Pt 17):3479-89. PubMed ID: 12865438 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin. Wu Y; Chen L; Cao L; Sheng W; Yang BB J Cell Sci; 2004 May; 117(Pt 11):2227-37. PubMed ID: 15126624 [TBL] [Abstract][Full Text] [Related]
16. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Andrae N; Kirches E; Hartig R; Haase D; Keilhoff G; Kalinski T; Mawrin C Eur J Cancer; 2012 Aug; 48(12):1831-41. PubMed ID: 22391574 [TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44. Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103 [TBL] [Abstract][Full Text] [Related]
18. Stimulation of glioma-cell migration by laminin and inhibition by anti-alpha3 and anti-beta1 integrin antibodies. Tysnes BB; Larsen LF; Ness GO; Mahesparan R; Edvardsen K; Garcia-Cabrera I; Bjerkvig R Int J Cancer; 1996 Sep; 67(6):777-84. PubMed ID: 8824548 [TBL] [Abstract][Full Text] [Related]